Intra-cellular Therapies Reiterates Full Year 2024 Caplyta Net Product Sales Guidance Of $645M-$675M
Portfolio Pulse from Benzinga Newsdesk
Intra-cellular Therapies has reaffirmed its full-year 2024 net product sales guidance for Caplyta, projecting revenues between $645 million and $675 million. This reiteration underscores the company's confidence in Caplyta's market performance and future sales prospects.
May 07, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-cellular Therapies reiterates its 2024 sales guidance for Caplyta, indicating strong confidence in the product's future market performance.
Reiterating sales guidance, especially with such optimistic figures, is a positive signal to investors about the company's confidence in its product and its market position. This could lead to increased investor confidence in ITCI, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100